Therabest Japan Inc. is a company endeavoring to create advanced fusion therapeutics by combining innovative new drugs with cell-based therapies to treat intractable diseases.

Mission Statement

Therabest Japan is dedicated to combining innovative biotechnology to create therapies that can improve the lives of many people by combating complex diseases.

Message from CEO

Therabest Japan Inc. is a research based pharmaceutical company that develops iPSC-derived cell therapies. There are many patients in the world who suffer from intractable diseases. One of our goals is to provide innovative treatment opportunities to those patients through our iPSC-derived cell therapy platform. We will also improve their quality of life by restoring patients’ immune systems to help them return to their daily lives. We will further advance our iPSC-derived cell therapy platform technology and pioneer the development of leading therapeutics through in-depth research and continual iteration of our technology.

About Therabest Japan

Therabest Japan is a biotechnology company combining expertise in induced Pluripotent Stem Cell (iPSC) technology, immunology, genome engineering, Extracellular Vesicles, and biomanufacturing to develop bioengineered off-the-shelf cell and extracellular vesicle therapies for oncology and regenerative medicine applications.
Therabest Japan is a subsidiary of Therabest, a Korean biopharma company that has developed enhanced iPSC-derived Natural Killer cell therapies to target diverse cancer types and treat immunological diseases. Therabest is headquartered in Seoul and has established a dedicated GMP production facility in Seoul.

What's New


Using induced Pluripotent Stem Cell (iPSC) technology, Therabest Japan is developing iPSC-derived cell therapy products, as well as iPSC-derived cell and organoid platforms for Extracellular Vesicle (EV) research. By utilizing gene editing in iPSCs, Extracellular Vesicles can be engineered to have enhanced potency and specificity. The goal of this work is to develop specialized, off-the-shelf EV therapeutics for use in cancer therapy and regenerative medicine.


Koichi Seriu, LLM

Tsukuba University, LL.M (Antitrust Law).

Worked for:
Nippon Boehringer Ingelheim Co., Ltd. Associate General Counsel

Shin-Il Kim, Ph.D

University of Wisconsin-Madison, Ph.D (Molecular biology)

Worked for:
University of California-San Francisco, Postdoctoral fellow
Center for iPS Cell Research and Application (CiRA), Kyoto University, Assistant Professor
aceRNA Technologies Co., Ltd, CSO Director, Division of R & D

About Us

Therabest Japan Inc.

Privacy Policy

1.  Compliance

We will strictly comply with Personal Information Protection Law, Guidelines on Personal Information Protection, and other laws and regulations on personal information protection whenever we handle personal information we acquired.

2. Safety management of personal information

We will take appropriate systematic, physical, human, and technical measures to protect personal information and will take the necessary safety management measures to prevent leakage, disappearance, or damage and the like of personal information we handle.

3. Rules to be observed on acquisition of personal information

We will strictly observe below items on acquisition, usage, and provision of personal information.

(1) Acquisition of personal information

We may acquire personal information of users of this website to the extent necessary for the maintenance of the website.

(2) Purposes of personal information usage

We will use personal information we acquired to the extent necessary to accomplish below purposes except for the case of requirement by law or a prior agreement by the person of the personal information.

i. Management, maintenance, or control of this website;

ii. Provision and introduction of our services through this website; and

iii. Conduct of questionnaire surveys to improve the quality of this website.

(3) Provision of personal information

We will not provide personal information we acquired upon agreement of the person of the personal information without his/her prior agreement to a third party except for the case law requires. We will disclose, correct, add, delete personal information or inform of the purpose of usage of such personal information in compliant with laws and regulations when the person of the personal information requires to do so, and sincerely correspond to his/her opinion and requirement.

4. Change of the purpose of personal information usage

In principle, we will not change the purpose of personal information usage stipulated in the previous paragraph unless we obtain a prior agreement by the person of the personal information. However, we may change the purpose after an official announcement to the extent that we may find a reasonable reason that the new purpose has a relevant relation with the current purpose.

5. Provision of personal information to a third party

We will examine the qualification of a third party when we assign all or a part of the management of acquired personal information to such a third party and conduct an adequate monitoring to the assignee in order for the safety control of the assigned personal information management.

6. Improvement/review of personal information

We will continuously review and improve the handling and management system of personal information.

7. Disposition of personal information

We will delete or dispose personal information we acquired when we find them unnecessary in the light of the purpose of usage. We will delete or dispose acquired personal information to the extent reasonable for execution our business with safe, necessary and appropriate method without any leakage risks.

Contact person for personal information

We will assign Dr. Teruo Susumu as a contact person who handles personal information matters.

CLIK #211, 6-3-7, Minatojima-minamimachi, Chuo-ku, Kobe city, 650-0047
Phone: +81-78-381-5894